JNJ-1661010 is a potent and selective is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. FAAH is a membrane bound serine hydrolase primarily responsible for the breakdown of the endogenous cannabinoid anandamide in the CNS. Increasing the amount of anandamide, which has analgesics properties, may be efficacious in the treatment of pain. According to the experimental data JNJ-1661010 may be useful clinically as broad-spectrum analgesics. Johnson & Johnson is developing JNJ-1661010 for the treatment of neuropathic pain. Preclinical development is being conducted in the US. In addition recent data demonstrated that JNJ-1661010 could be useful in the treatment of arthritis and parkinson's disease. JNJ-1661010 inhibits myometrial contractility, without un-specific relaxing effects on the smooth muscle.